Progenics Pharma (PGNX) Tops Q2 Views; Revs Heavy
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q2 EPS of $1.64, versus the analyst estimate of ($0.25). Revenue for the quarter came in at $74.41 million versus the consensus estimate of $9.98 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- Seritage Growth Properties (SRG) Reports Q2 Loss of $0.13
- Femasys Inc. (FEMY) Misses Q2 EPS by 20c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
